Please login first
Photodynamic therapy on a human lung cancer cell line a549 with new bodipy photosensitizers
* 1, 2 , 1, 3, 4 , 2 , 1, 3, 4 , 2
1  Biophysics Institute, Faculty of Medicine, University of Coimbra, Portugal.;
2  Faculty of Science and Technology, University of Coimbra, Portugal;
3  CNC.IBILI, University of Coimbra, Portugal.
4  Institute for Clinical and Biomedical Research (iCBR) area of Environment Genetics and Oncobiology (CIMAGO), Faculty of Medicine, University of Coimbra, Portugal;

Published: 11 November 2019 by MDPI in 5th International Electronic Conference on Medicinal Chemistry session Posters

Lung cancer is the most incident and the deadliest cancer for both men and women. Therefore, the need for new and more effective therapies with fewer side effects is a concern. Photodynamic Therapy (PDT) relies on the administration of a photosensitizer that is subsequently activated by irradiation with light of appropriate wavelength. As a result, reactive oxygen species (ROS) are produced leading to cell death. PDT use in the treatment of cancer is still limited, due to the low number of new approved drugs. In light with this, this work aims to develop new photosensitizers for PDT. As an alternative class of the porphyrin-based photosensitizers, two compounds of the family of the boron−dipyrromethenes (BODIPY) have been synthesized and evaluated on the human lung cancer cell line A549. In this study, we used the MTT and SRB assays to assess the cytotoxicity of the compounds with concentrations ranging from 0,1 to 50 μM. Both compounds are photocytotoxics at the higher concentration studied. The most effective compound in the photocytotoxicity studies was the BODIPY 2 when used in a concentration of 10 and 50 µM. These promising results uphold further studies.

Keywords: bodipy, photodinamic therapy, biomaterials